Smaller Default Larger
  • Intravenous immunoglobulin (IVIG) is a plasma product derivative predominantly composed of monomeric IgG molecules from tens of thousands of individual blood donors. 

  • When given in high-doses it possesses useful immunomodulatory properties, but may also cause haemolytic reactions. 

  • While patients with non-O blood group receiving doses ≥ 2 g/kg appear to be at highest risk, there are likely other patient factors that influence susceptibility to IVIG-associated hemolysis. 

  • To date, most studies have relied on either in vitro experiments or capture of reports submitted to passive surveillance systems, strategies which both have significant limitations.